The role of tumor stem cells and the immune microenvironment in the pathogenesis of lung cancer: mechanisms of interaction and research prospects
Authors:
- D. A. KharagezovDKD. A. Kharagezov
- A. A. AntonyanAAA. A. Antonyan
- E. Yu. ZlatniEZE. Yu. Zlatni
- A. B. SagakyantsASA. B. Sagakyants
- E. A. MirzoyanEME. A. Mirzoyan
- T. G. AyrapetovaTAT. G. Ayrapetova
- I. A. LeymanILI. A. Leyman
- A. G. MilakinAMA. G. Milakin
- O. N. StateshnyOSO. N. Stateshny
- K. D. IozefiKIK. D. Iozefi
- M. A. HomidovMHM. A. Homidov
- E. A. AlekseevEAE. A. Alekseev
Open Access
- 13 November 2024
- journal article
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 5 (4) , 58-70
Abstract
Despite significant advances in the treatment of malignant neoplasms, the issue of therapy resistance mediated by cancer stem cells (CSCs) necessitates the development of new treatment strategies. Studying the role of CSCs and the immune microenvironment in the pathogenesis of cancer, particularly non-small cell lung cancer (NSCLC), is a pressing issue in modern oncology. This paper is based on an extensive analysis of recent research and aims to study the mechanisms underlying the development of NSCLC.The origin of CSCs, their markers, and the main signaling pathways involved in regulating their activity are considered. Special attention is paid to the influence of CSCs on the progression of lung cancer and the mechanisms underlying their therapy-mediated resistance. Various approaches to treating lung cancer targeting CSCs, focusing on targeted therapy aimed at specific molecular targets, are highlighted.The important role of the tumor immune microenvironment in the pathogenesis of lung cancer and its impact on CSCs is emphasized. Mechanisms of immune response regulation in tumors and the potential use of immunotherapy to improve lung cancer treatment outcomes are discussed. The article also reviews modern diagnostic and treatment methods, including molecular-genetic and immunohistochemical approaches.This paper work represents a review of current knowledge on the mechanisms of lung cancer development and is significant for understanding tumor biology and developing new treatment methods. The need for an interdisciplinary approach and comprehensive use of modern diagnostic and therapeutic methods to improve the prognosis and survival rates of NSCLC patients is emphasized. Special attention is given to the prospects of using combined therapeutic approaches, including targeted drugs and immunotherapy, aimed at suppressing CSC activity and modifying the tumor microenvironment.In conclusion, a deep understanding of the molecular mechanisms regulating CSC activity and their interaction with the tumor microenvironment opens new opportunities for developing effective treatment strategies. This review underscores the need for further research in this area to ensure more successful treatment and improved quality of life for lung cancer patients.Keywords
This publication has 61 references indexed in Scilit:
- The evolving landscape of biomarker testing for non-small cell lung cancer in EuropeLung Cancer, 2021
- Cancer stem cells: Road to therapeutic resistance and strategies to overcome resistanceBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2020
- CD44(+) tumor cells promote early angiogenesis in head and neck squamous cell carcinomaCancer Letters, 2019
- Markers of pancreatic cancer stem cells and their clinical and therapeutic implicationsMolecular Biology Reports, 2019
- Concise Review: Emerging Drugs Targeting Epithelial Cancer Stem-Like CellsStem Cells, 2017
- Organoid Culture of Human Cancer Stem Cells2016
- CD44 is a Multidomain Signaling Platform that Integrates Extracellular Matrix Cues with Growth Factor and Cytokine Signals2014
- Glycine Decarboxylase Activity Drives Non-Small Cell Lung Cancer Tumor-Initiating Cells and TumorigenesisCell, 2012
- Growth-Inhibitory and Tumor- Suppressive Functions of p53 Depend on Its Repression of CD44 ExpressionCell, 2008
- Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosisLung Cancer, 2006